stoxline Quote Chart Rank Option Currency Glossary
  
Incannex Healthcare Limited (IXHL)
0.2169  -0.007 (-2.95%)    06-20 13:25
Open: 0.2216
High: 0.2228
Volume: 11,457,068
  
Pre. Close: 0.2235
Low: 0.2117
Market Cap: 20(M)
Technical analysis
2025-06-20 12:48:11 PM
Short term     
Mid term     
Targets 6-month :  0.84 1-year :  1.23
Resists First :  0.72 Second :  1.05
Pivot price 0.2
Supports First :  0.17 Second :  0.14
MAs MA(5) :  0.21 MA(20) :  0.2
MA(100) :  0.76 MA(250) :  1.53
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  54.7 D(3) :  45.7
RSI RSI(14): 46.8
52-week High :  3.5 Low :  0.07
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IXHL ] has closed below upper band by 28.8%. Bollinger Bands are 89.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.24 - 0.24 0.24 - 0.24
Low: 0.21 - 0.22 0.22 - 0.22
Close: 0.22 - 0.22 0.22 - 0.23
Company Description

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

Headline News

Wed, 18 Jun 2025
Incannex Achieves Milestone in Sleep Apnea Drug Trial - TipRanks

Wed, 18 Jun 2025
Revolutionary Oral Sleep Apnea Drug Nears Results: Incannex Phase 2 Trial Reaches Final Stage - Stock Titan

Tue, 17 Jun 2025
Incannex Healthcare Announces Psychedelic Therapies Joint Venture - TipRanks

Tue, 17 Jun 2025
Groundbreaking Partnership: Incannex and Mind Medicine Launch Australia's Largest Psychedelic Therapy Center - Stock Titan

Thu, 12 Jun 2025
Incannex Cancels All Warrants, Removes 347M Share Dilution Before Critical Sleep Apnea Trial Data - Stock Titan

Thu, 29 May 2025
Incannex Healthcare Advances RePOSA Trial to Phase 3 - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 0 (M)
Shares Float 94 (M)
Held by Insiders 2.823e+007 (%)
Held by Institutions 26.1 (%)
Shares Short 196 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.025e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -20 %
Return on Assets (ttm) 952 %
Return on Equity (ttm) -76.8 %
Qtrly Rev. Growth 98000 %
Gross Profit (p.s.) 0
Sales Per Share -81.73
EBITDA (p.s.) 39676.1
Qtrly Earnings Growth -1.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -15 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.98
Stock Dividends
Dividend 0
Forward Dividend 8.43e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android